EMEA-000317-PIP02-18

Key facts

Invented name
Edurant
Active substance
rilpivirine
Therapeutic area
Infectious diseases
Decision number
P/0039/2019
PIP number
EMEA-000317-PIP02-18
Pharmaceutical form(s)
Suspension for injection
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Intramuscular use
Contact for public enquiries
Janssen-Cilag International N.V.

Tel.  +32 14602111
E-mail: contact@janssen-emea.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating